Physician profile
Poorva Vaidya
NPI 1407387566
$3,055.52
in general payments reported to CMS, 2019-2025
7 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.30 · 2023: $391 · 2024: $142 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,000 · Food and Beverage: $943 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,000.00 |
| Food and Beverage | $942.69 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $2,310.56 | 2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $270.81 | 2023 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $120.42 | 2023 | Ultomiris |
| Regeneron Pharmaceuticals, INC. | $115.89 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $96.30 | 2021 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poorva Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.